Compare SLGN & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLGN | KALA |
|---|---|---|
| Founded | 1987 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 13.3M |
| IPO Year | 1994 | 2017 |
| Metric | SLGN | KALA |
|---|---|---|
| Price | $38.76 | $0.52 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 3 |
| Target Price | ★ $52.78 | $31.50 |
| AVG Volume (30 Days) | ★ 915.0K | 353.5K |
| Earning Date | 04-29-2026 | 04-15-2026 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | 4.65 | ★ 67.39 |
| EPS | ★ 1.31 | N/A |
| Revenue | ★ $4,489,927,000.00 | N/A |
| Revenue This Year | $4.99 | N/A |
| Revenue Next Year | $2.20 | N/A |
| P/E Ratio | $29.31 | ★ N/A |
| Revenue Growth | ★ 0.92 | N/A |
| 52 Week Low | $35.68 | $0.07 |
| 52 Week High | $49.41 | $20.58 |
| Indicator | SLGN | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 32.53 | 30.22 |
| Support Level | $37.85 | $0.10 |
| Resistance Level | $38.94 | $0.72 |
| Average True Range (ATR) | 0.95 | 0.09 |
| MACD | -0.26 | 0.00 |
| Stochastic Oscillator | 13.42 | 2.92 |
Silgan Holdings Inc is a manufacturer of sustainable rigid packaging solutions for the world's essential consumer goods products. Its products include: dispensing and specialty closures for fragrance and beauty, food, beverage, personal and health care, home care and lawn and garden products; steel and aluminum containers for pet and human food and general line products; and custom designed plastic containers for pet and human food, consumer health and pharmaceutical, personal care, home care, lawn and garden and automotive products.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.